Borden was noted as being "instrumental in navigating Horizon Pharma PLC through four completed acquisitions, including the acquisition of Vidara Therapeutics International PLC for $660 million." She was also noted by the publication for advising Horizon on its $1.1 billion acquisition of Hyperion Therapeutics Inc.

When interviewed by the Daily Journal, Dauchy noted, "Our group raised more venture capital on the fund side than anybody else in the country. We've had closings on 95 funds that were vintage 2015 funds. When you include all funds that have had closings in 2015, the number is 151."

In 2015 to date, Kim has worked on at least 24 completed public offerings including 10 IPOs. Specializing in the technology, life sciences and health care industries, Kim noted, "The technology and life science companies in this space are doing amazing things and making the world a better place. I really enjoy being part of that process."

Neal was highlighted for successfully gaining victories for multiple clients this year. The Daily Journal noted Cooley's work representing CEO Meg Whitman in the HP Autonomy securities litigation as well as the successful arbitration win for Gilead Sciences against F. Hoffmann-La Roche AG.